Watson Laboratories receives FDA approval for Zarah tablets

Sep 7 2010NewsGuard 100/100 Score

Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zarah™ (drospirenone and ethinyl estradiol tablets) 3 mg/0.03 mg, the generic equivalent to Bayer's Yasmin®. Watson has begun shipping the product.  Bayer's lawsuit against Watson alleging that Watson's product infringes Bayer's U.S. Patent No. 5,569,652 remains pending in the U.S. District Court for the Southern District of New York.

Yasmin® and its generic equivalents had total U.S. sales of approximately $97 million for the twelve months ending June 30, 2010, according to IMS Health.  Watson's Zarah™ tablets are indicated for the prevention of pregnancy in women who elect to use an oral contraceptive.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Key triggers for food allergies in children after organ transplants
High levels of microplastics found in prostate tumors, possibly linked to take-out food
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group
Six common flying with food allergies myths
Limiting fast-food outlets can reduce childhood overweight and obesity
Frequent ultra-processed food consumption raises mortality risks, especially in women
Online food shopping: Are you getting the information you need?
Ultra-processed food linked to weight gain and lower well-being in adolescents

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Living in food deserts during early childhood raises long-term obesity risk